← FDA DRUG APPROVALS

FDA ANDA · ANDA200744

TACROLIMUS

Sponsor: FOUGERA PHARMS INC

APPLICATION
ANDA200744
TYPE
ANDA
ORIGINAL APPROVAL
2014-09-09
LATEST ACTION
2023-06-02
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Prescription

Products

TACROLIMUSPrescription
TACROLIMUS 0.1% · OINTMENT · TOPICAL
TACROLIMUSPrescription
TACROLIMUS 0.03% · OINTMENT · TOPICAL

Approval history

2023-06-02Labeling · Supplement 11 · standardAP
2015-04-29Manufacturing (CMC) · Supplement 1 · unknownAP
2014-09-09Not Applicable · OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →